Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Phase 1/2 Recruiting
74 enrolled
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Phase 1/2 Recruiting
56 enrolled
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Phase 1/2 Recruiting
54 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
MK-9999-01A
Phase 1/2 Recruiting
90 enrolled
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Phase 1/2 Recruiting
27 enrolled
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Phase 1/2 Recruiting
94 enrolled
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Phase 1/2 Recruiting
180 enrolled
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase 1/2 Recruiting
104 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
LiFFT
Phase 1/2 Recruiting
63 enrolled
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Phase 1/2 Recruiting
63 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Phase 1/2 Recruiting
98 enrolled
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/2 Recruiting
90 enrolled
SPEARHEAD-3 Pediatric Study
Phase 1/2 Recruiting
20 enrolled
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
Phase 1/2 Recruiting
55 enrolled
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
Phase 1/2 Recruiting
39 enrolled
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Phase 1/2 Recruiting
60 enrolled
Evaluate the Safety and Clinical Activity of HH2853
Phase 1/2 Recruiting
254 enrolled
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Phase 1/2 Recruiting
139 enrolled
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Phase 1/2 Recruiting
86 enrolled
A Study of ERAS-601 in People With Chordoma
Phase 1/2 Recruiting
46 enrolled
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Phase 1/2 Recruiting
112 enrolled
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Phase 1/2 Recruiting
6 enrolled
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 Recruiting
27 enrolled
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/2 Recruiting
75 enrolled
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
225 enrolled
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Phase 1/2 Recruiting
62 enrolled
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Phase 1/2 Recruiting
49 enrolled
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/2 Recruiting
3 enrolled
NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
Phase 1/2 Recruiting
80 enrolled
PHANTOM
Phase 1/2 Recruiting
26 enrolled
BAH2573-103
Phase 1/2 Recruiting
60 enrolled
TRIDENT-1
Phase 1/2 Recruiting
500 enrolled 2 FDA
HTL0039732 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
150 enrolled
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
70 enrolled
DFMO
Phase 1/2 Recruiting
15 enrolled
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
Phase 1/2 Recruiting
48 enrolled
PEEL-224
Phase 1/2 Recruiting
59 enrolled
PRIME
Phase 1/2 Recruiting
195 enrolled
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Phase 1/2 Recruiting
95 enrolled
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
Phase 1/2 Recruiting
250 enrolled
ROLN-B7-H3
Phase 1/2 Recruiting
32 enrolled
PerVision
Phase 1/2 Recruiting
30 enrolled
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Phase 1/2 Recruiting
358 enrolled
A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma
Phase 1/2 Recruiting
65 enrolled
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Phase 1/2 Recruiting
100 enrolled
FaR-RMS
Phase 1/2 Recruiting
1,672 enrolled
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Phase 1/2 Recruiting
200 enrolled